07/10/2025 4:08 PM | KOZARICH JOHN W (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2025 8:28 AM | Ligand Pharmaceuticals (Reporting) Pelthos Therapeutics Inc. (Issuer)
| Form 3 Initial statement of beneficial ownership of securities | |
07/03/2025 8:33 AM | Ligand Pharmaceuticals (Reporting) Pelthos Therapeutics Inc. (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/02/2025 6:31 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/02/2025 6:32 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/02/2025 6:32 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/02/2025 6:03 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 3/A | |
07/02/2025 6:10 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/24/2025 7:29 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/23/2025 4:07 PM | Ligand Pharmaceuticals (Subject) Reardon Andrew (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/12/2025 4:51 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for LGND and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
06/10/2025 6:39 PM | Aryeh Jason (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2025 6:39 PM | Gray Nancy Ryan (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2025 6:20 PM | Haas Jason (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2025 6:21 PM | KOZARICH JOHN W (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2025 6:21 PM | Ligand Pharmaceuticals (Issuer) Sabba Stephen L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2025 6:21 PM | Ligand Pharmaceuticals (Issuer) Zimmermann Martine (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2025 6:24 PM | LAMATTINA JOHN L (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2025 5:49 PM | Ligand Pharmaceuticals (Subject) Reardon Andrew (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/02/2025 7:05 PM | KOZARICH JOHN W (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/02/2025 7:06 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/14/2025 11:31 AM | JANUS HENDERSON GROUP PLC (Filed by) Ligand Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
05/13/2025 7:04 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/13/2025 7:05 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/08/2025 6:06 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/17/2025 5:08 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/16/2025 8:34 AM | Ligand Pharmaceuticals (Issuer) Sabba Stephen L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/06/2025 5:54 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/06/2025 5:55 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/06/2025 5:55 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/28/2025 3:02 PM | Ligand Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/27/2025 6:06 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/19/2025 7:44 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/19/2025 7:37 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/19/2025 7:38 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/14/2025 11:36 AM | JANUS HENDERSON GROUP PLC (Filed by) Ligand Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
12/26/2024 7:32 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/23/2024 7:19 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/06/2024 6:55 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/02/2024 7:05 PM | LAMATTINA JOHN L (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/27/2024 3:44 PM | LAMATTINA JOHN L (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Trump wipes out trillions overnight… (Ad) Is there anybody more powerful than Donald Trump right now?
In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones…
Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move. Whether you take some of that wealth for yourself depends on if you watch this controversial exposé |
11/14/2024 2:19 PM | JANUS HENDERSON GROUP PLC (Filed by) Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/08/2024 4:34 PM | GOLDMAN SACHS GROUP INC (Filed by) GOLDMAN SACHS GROUP INC (Filed by) Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024 6:11 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/01/2024 3:07 PM | Ligand Pharmaceuticals (Subject) MACQUARIE GROUP LTD (Filed by)
| Form SC 13G/A | |
09/25/2024 7:54 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/24/2024 6:41 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/24/2024 6:41 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/23/2024 4:27 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/23/2024 4:30 PM | Ligand Pharmaceuticals (Subject) Reardon Andrew (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/20/2024 5:12 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/20/2024 4:39 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/19/2024 4:50 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/18/2024 6:55 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/30/2024 8:00 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/30/2024 7:56 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/28/2024 3:39 PM | Ligand Pharmaceuticals (Subject) Reardon Andrew (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024 7:15 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/22/2024 5:05 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024 4:21 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/09/2024 4:52 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/09/2024 4:16 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/07/2024 3:30 PM | Ligand Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
07/17/2024 4:10 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |